Mainz BioMed N.V.
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
F
Overview
Corporate Details
- ISIN(s):
- NL0015000LC2 (+3 more)
- LEI:
- 894500XWJE7LIJNYQ547
- Country:
- Germany
- Address:
- Robert-Koch-Strasse 50, 55129 Mainz
- Website:
- https://mainzbiomed.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Mainz BioMed N.V. is a molecular genetics company that develops and commercializes market-ready in-vitro diagnostic (IVD) solutions for the early detection of life-threatening conditions. The company's flagship product, ColoAlert®, is a non-invasive, at-home screening test for colorectal cancer (CRC) marketed in Europe. Mainz BioMed is also advancing its product pipeline with proprietary genetic testing methods for other deadly conditions, including pancreatic cancer, to provide accessible and reliable early detection solutions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
Date | Filing | Language | Size | Actions | |
---|---|---|---|---|---|
2025-10-08 15:00 |
Regulatory News Service
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel …
|
English | 12.2 KB | ||
2025-09-30 14:01 |
Regulatory News Service
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Sc…
|
English | 12.1 KB | ||
2025-09-23 14:01 |
Regulatory News Service
Mainz Biomed Announces Commercial Launch of ColoAlert in Switzerland
|
English | 11.5 KB | ||
2025-09-02 14:01 |
Regulatory News Service
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
|
English | 11.2 KB | ||
2025-08-13 14:01 |
Regulatory News Service
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert
|
English | 11.6 KB | ||
2025-07-23 14:01 |
Business and Financial Review
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for…
|
English | 11.2 KB | ||
2025-07-15 14:01 |
Earnings Release
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colore…
|
English | 15.5 KB | ||
2025-06-25 14:01 |
Regulatory News Service
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Scr…
|
English | 11.1 KB |
Automate Your Workflow. Get a real-time feed of all Mainz BioMed N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Mainz BioMed N.V. via our API.
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
No insider transactions recorded for this company. |